These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36037304)

  • 1. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
    Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
    Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
    Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
    Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
    Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P
    Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
    Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
    Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
    Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
    Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y; Liu Q; Zuo T; Wei G; Jiao S
    Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
    Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
    Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
    Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
    Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.